Cargando…
Burden on Oncologists When Communicating the Discontinuation of Anticancer Treatment
OBJECTIVE: Communicating the discontinuation of anticancer treatment to patients is a difficult task. The primary aim of this study was to clarify the level of oncologist-reported burden when communicating about discontinuation of an anticancer treatment. The secondary aims were (i) to identify the...
Autores principales: | Otani, Hiroyuki, Morita, Tatsuya, Esaki, Taito, Ariyama, Hiroshi, Tsukasa, Koichiro, Oshima, Akira, Shiraisi, Keiko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3146312/ https://www.ncbi.nlm.nih.gov/pubmed/21764830 http://dx.doi.org/10.1093/jjco/hyr092 |
Ejemplares similares
-
Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4877 in Japanese Patients with Solid Tumors
por: Esaki, Taito, et al.
Publicado: (2011) -
Focus on anticancer therapy-induced cardiotoxicity from the perspective of oncologists
por: Liu, Binliang, et al.
Publicado: (2022) -
Oncologists' Perspective: When Cancer Encounters COVID‐19
por: Gao, Zhaoya, et al.
Publicado: (2020) -
When Should Oncologists Use the Words Hope and Cure?
por: Kiely, Belinda E, et al.
Publicado: (2020) -
Out-of-Pocket Spending for Cancer Medication, Financial Burden, and Cost Communication with Oncologists in the Last Six Months of Life in Israel
por: Tur-Sinai, Aviad, et al.
Publicado: (2021)